Le Lézard
Classified in: Science and technology
Subjects: PER, PET

Hologenix, LLC, the manufacturer of Celliant® technology, adds industry veteran Jim Calhoun to board of directors, names Bill Werlin chairman of the board


SANTA MONICA, Calif., Oct. 17, 2017 /PRNewswire/ -- Hologenix, LLC today announced the appointment of Jim Calhoun to its Board of Directors. Calhoun is former CEO and president of Converse and an executive in the footwear, apparel and retail industries. 

In addition, Bill Werlin was elected chairman of the board. Werlin joined the board in 2016 and was most recently president of The North Face.

Celliant is a responsive textile technology for apparel, bedding and veterinary products. Celliant's patented technology harnesses and recycles the body's natural energy through the use of fibers, and is used globally by 60+ companies. In July, the FDA classified it as a medical device and general wellness product.

"Jim has spent 25 years working at some of the most successful and iconic global brands in the consumer products industry, including Converse, Levi Strauss, The Walt Disney Company, Nautica and Nike," said Werlin, chairman of the board. "He will be a strong addition to the board and I am pleased to welcome him."

"Jim's expertise will be invaluable as tier-1 brands continue to adapt Celliant technology. We have exciting things coming down the pipeline and our board will be instrumental in guiding our growth strategy during this pivotal time," said Seth Casden, CEO of Hologenix, LLC.

Calhoun led the resurgence of the Converse brand and business worldwide. Prior to that, he served as CEO of Hurley International LLC, an affiliate of Nike Inc. Before Hurley, he served as the president of the Dockers Brand and executive VP at Levi Strauss & Co. in San Francisco.

About Hologenix, LLC and Celliant®

Hologenix, LLC, Celliant's (www.celliant.com) parent company, is committed to developing and marketing products that improve people's lives. Celliant is a patented clinically-tested textile technology that harnesses and recycles the body's natural energy through the medium of fibers. The U.S. Food and Drug Administration (FDA) has classified it as a medical device and general wellness product, as defined in Section 201(h) of the Federal Food, Drug and, Cosmetic Act. Celliant's applied science utilizes a blend of minerals and proprietary ingredients embedded into the core of the fiber. Use of products containing this technology has been clinically proven to improve athletic performance, sleep quality and wellness.

 

SOURCE Hologenix, LLC


These press releases may also interest you

at 22:15
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

at 22:10
Getech, a world-leading locator of subsurface resources, is pleased to announce it has won a new contract with East Star Resources, a London-listed company focused on copper exploration, to locate porphyry copper...

at 22:00
BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. , today announced the final April 2024 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on April...

at 22:00
At the recent Global Food Safety Initiative (GFSI) conference in Singapore, conversations highlighted the need for the food industry to adapt swiftly to changes in the risk landscape and incorporate strategies that go beyond compliance to competitive...

at 21:30
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...



News published on and distributed by: